Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06888089 · ClinicalTrials.gov registry record · NA

Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
20,707
Enrollment target

NCT06888089: Completed NA study, sponsored by Dana-Farber Cancer Institute.

NCT06888089 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20,707 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1376% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06888089, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
20,707 participants
Enrollment target

Study Summary

This study aims to evaluate the effectiveness of proactive notifications to treating oncologist to optimize participant accrual to clinical trials by utilizing the MatchMiner AI platform. This study compares the standard MatchMinder AI access method to two enhanced recruitment methods.

Primary Outcome

This measure assesses the proportion of patients in each study arm who enroll in any Dana-Farber Cancer Institute (DFCI) therapeutic clinical trial involving anti-cancer systemic therapy during the intervention period. Trial enrollment data will be pulled from the institutional OnCore database.

Interventions

  • OTHER AI-assisted MatchMiner Platform

Trial Details

FieldValue
Enrollment Target 20,707 participants
Start Date 2023-01-30
Est. Completion 2024-07-15
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT06888089 record still lists

NCT06888089 is an interventional study that assigns participants to a tested intervention. Its 20,707 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1376% higher).

The record links to 0 conditions, and to 1 intervention - of which AI-assisted MatchMiner Platform is the first listed.

NCT06888089 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06888089 about?

NCT06888089 is a clinical study titled "Deep Clinical Trajectory Modeling to Optimize Accrual to Cancer Clinical Trials". This study aims to evaluate the effectiveness of proactive notifications to treating oncologist to optimize participant accrual to clinical trials by utilizing the MatchMiner AI platform. This study compares the standard MatchMinder AI access method to two enhanced recruitment methods.

What is the current status of trial NCT06888089?

This trial is currently completed. It is a NA study. The enrollment target is 20,707 participants. The study started on 2023-01-30. Estimated completion is 2024-07-15.

What interventions are being tested in trial NCT06888089?

The interventions under investigation include: AI-assisted MatchMiner Platform (OTHER).

Who is sponsoring clinical trial NCT06888089?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06888089's enrollment target sits among peer trials

20,707 10th of 2000 higher than 1,991 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07213531 · 21,000 participants

    Enhanced Valves Interventions and Safe AI Generated End Results

  • NCT06062342 · 20,400 participants · NA

    Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities

  • NCT06047041 · 21,350 participants · NA

    Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students

  • NCT00271180 · 20,000 participants

    Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06888089, the US trial registry maintained by the National Library of Medicine. NCT06888089 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.